Every time Charles publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

You may have heard that "vibe coding" is Collins Dictionary's word of the year for 2025. So, if you've been nodding and smiling every time you hear the phrase, it ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant.

Earlier this year, former OpenAI exec Andrej Karpathy coined a new term — “vibe coding” — for using artificial intelligence to rapidly develop software using natural language prompts. But the approach ...

Replimune (REPL) stock underwent a major rally on Monday after the biotechnology company announced results from its resubmission of a Biologics License Application (BLA) for “RP1 in combination with ...

Vibe coding platforms are handy tools in the AI era, making it easier for users to create and generate web and mobile apps with little-to-no coding knowledge. Some options provide full-on no-code ...

We may receive a commission from our partners if you click on a link to review or purchase a product or service. Click to Learn More Vibe coding is a software development practice that uses an AI ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...